Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Mitsubishi Tanabe Pharma (4508)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Mitsubishi Tanabe Pharma historical data, for real-time data please try another search
2,006.0 0.0    0.00%
26/02 - Closed. Currency in JPY ( Disclaimer )
Type:  Equity
Market:  Japan
ISIN:  JP3469000008 
  • Volume: 0
  • Bid/Ask: 2,006.0 / 2,009.0
  • Day's Range: 2,006.0 - 2,009.0
Mitsubishi Tanabe Pharma 2,006.0 0.0 0.00%

4508 Balance Sheet

 
Featured here, the Balance Sheet for Mitsubishi Tanabe Pharma, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
Advanced Balance Sheet
Period Ending: 2019
31/12
2019
30/09
2019
30/06
2019
31/03
Total Current Assets 603933 590125 574671 588433
Cash and Short Term Investments 369336 375959 366388 383282
Cash - - - -
Cash & Equivalents 97657 88545 105379 111850
Short Term Investments 271679 287414 261009 271432
Total Receivables, Net 132523 114336 119984 116951
Accounts Receivables - Trade, Net 132523 114336 119984 116951
Total Inventory 72935 78604 75007 75559
Prepaid Expenses - - - -
Other Current Assets, Total 29139 21226 13292 12641
Total Assets 1077547 1055880 1045456 1056286
Property/Plant/Equipment, Total - Net 84198 80997 83540 73595
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net 90234 89934 91289 91640
Intangibles, Net 209071 203730 203190 206918
Long Term Investments 55379 57824 59052 62539
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 34732 33270 33714 33161
Other Assets, Total - - - -
Total Current Liabilities 100243 88841 86661 91699
Accounts Payable 41070 33369 33181 31477
Payable/Accrued - - - -
Accrued Expenses - - - -
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 16 15 34 45
Other Current liabilities, Total 59157 55457 53446 60177
Total Liabilities 199452 174330 164271 158682
Total Long Term Debt 1920 142 148 150
Long Term Debt 1920 142 148 150
Capital Lease Obligations - - - -
Deferred Income Tax 37590 36943 38288 39234
Minority Interest 12621 12036 12760 12728
Other Liabilities, Total 47078 36368 26414 14871
Total Equity 878095 881550 881185 897604
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 50000 50000 50000 50000
Additional Paid-In Capital 448704 449620 449993 451253
Retained Earnings (Accumulated Deficit) 377592 381765 379732 387964
Treasury Stock - Common -1022 -1018 -1040 -1040
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - 14973 -
Other Equity, Total 2821 1183 -12473 9427
Total Liabilities & Shareholders' Equity 1077547 1055880 1045456 1056286
Total Common Shares Outstanding 560.78 560.79 560.78 560.78
Total Preferred Shares Outstanding - - - -
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4508 Comments

Write your thoughts about Mitsubishi Tanabe Pharma
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email